Vicore Pharma Presents ASPIRE Phase 2b Trial Design for Buloxibutid AT2R Agonist in Idiopathic Pulmonary Fibrosis at ERS Congress Monday September 7
Vicore Pharma Holding AB (STO: VICO) presented the trial-design abstract for its global 52-week Phase 2b ASPIRE trial of buloxibutid (a first-in-class oral angiotensin II type 2 receptor agonist small molecule) in idiopathic pulmonary fibrosis at the European Respiratory Society Congress 2026 on Monday September 7, 2026 in Barcelona. The randomized double-blind placebo-controlled parallel-group trial enrolled more than 360 IPF patients across 14 countries and 100 sites (29 in the United States), stratified between patients on background nintedanib standard of care and those without antifibrotic therapy. The primary endpoint is change in forced vital capacity (FVC) over 52 weeks, the regulatory endpoint for IPF. Buloxibutid activates AT2R to promote alveolar-epithelial-cell repair and downregulate aberrant fibrotic signalling. Enrollment completed in April 2026; topline results are guided for mid-2027 with cash runway into H2 2028. The ASPIRE readout will land in a crowded IPF competitive landscape following the March 2026 FDA approval of Boehringer's nerandomilast (BI 1015550) as the first non-antifibrotic mechanism approved for IPF in over a decade.